FTC alleges CVS's PBM manipulated insulin prices.
Proposed deal aims to improve access to affordable insulin.
Settlement could significantly reduce costs for consumers.
Briefing: FTC Strikes Proposed Deal with CVS Over Insulin Price Manipulation
Strategic angle: Settlement expected to save Americans up to $7 billion in out-of-pocket costs over the next decade.